<DOC>
	<DOCNO>NCT01763671</DOCNO>
	<brief_summary>The study objective evaluate efficacy paclitaxel-bevacizumab comparing docetaxel . Docetaxel standard treatment 2nd 3rd line lung cancer . It validate numerous clinical trial sometimes toxicity difficult manage . Bevacizumab antiangiogenic treatment validate numerous clinical trial association platinum first ligne . Different clinical preclinical data suggest could exist synergy paclitaxel bevacizumab . This association already use metastatic breast cancer , permit almost double response rate progression free survival . In lung cancer , association evaluate two retrospective study demonstrate benefit favourable safety profile .</brief_summary>
	<brief_title>Paclitaxel-bevacizumab Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>2nd 3rd line non squamous non small cell lung cancer stage III IV Document progression time inclusion . At least , one previous chemotherapy line platinum . Patient previous treatment bevacizumab include . Patient active mutation EGFR must line chemotherapy platinum one Tyrosine kinase inhibitor EGFR . Patient ALK rearrangement must least one line chemotherapy platinum one crizotinib . Mixed cancer small cell non small cell squamous lung cancer . Central nervous system symptomatic metastasis require immediate cerebral radiotherapy patient previous treatment taxane ( docetaxel , paclitaxel ) . Perioperatory chemotherapy chemoradiotherapy taxane allow stop 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Paclitaxel bevacizumab</keyword>
</DOC>